Biosimilar Reform & Competitive Landscape Transformation
Description
Strategic analysis of biosimilar market transformation. 118 biologics lose patent 2025-2034 ($232B opportunity). Simplified approval pathways reducing development costs. Covers originator response strategies and next-generation product acceleration.
Table of Contents
76 Pages
- EXECUTIVE SUMMARY
- 1.1 Biosimilar Market Evolution
- 1.2 Patent Cliff Impact Analysis
- 2.0 REGULATORY PATHWAY CHANGES
- 2.1 Simplified Approval Pathways
- 2.2 Development Cost Reduction
- 2.3 Global Harmonization Trends
- 3.0 ORIGINATOR RESPONSE STRATEGIES
- 3.1 Next-Generation Product Launch
- 3.2 Patent Stacking Approaches
- 3.3 Patient Loyalty Programs
- 4.0 COMPETITIVE DYNAMICS
- 4.1 Biosimilar Entrant Analysis
- 4.2 Manufacturing Competition
- 4.3 Pricing Pressure Assessment
- 5.0 PORTFOLIO OPTIMIZATION
- 5.1 At-Risk Asset Management
- 5.2 Pipeline Acceleration
- 5.3 Market Share Defense
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
